机构：[1]Guangzhou University of Chinese Medicine, Guangzhou 510006, Guangdong Province, China.[2]Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, Guangdong Province, China.[3]Institute of Tumor, Guangzhou University of Chinese Medicine, Guangzhou 510006, Guangdong Province, China.[4]Guangdong Provincial Key Laboratory of New Drug Development and Research of Chinese Medicine, Mathematical Engineering Academy of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou 510006, Guangdong Province, China.深圳市中医院深圳医学信息中心[5]The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen 510275, Guangdong Province, China.深圳医学信息中心中国医学科学院阜外医院深圳医院[6]Army Medical University, Chongqing Municipality 400038, China.[7]The First Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou 510405, Guangdong Province, China.深圳市中医院深圳医学信息中心[8]Guangdong Academy of Population Development, Guangzhou 510600, Guangdong Province, China.[9]South China University of Technology, Guangzhou 510641, Guangdong Province, China.
The minimum clinical important differences (MCIDs) of resilience instruments in patients with cancer have not been comprehensively described. This study was designed to evaluate MCIDs of 10-item and 25-item resilience scales specific to cancer (RS-SC-10 and RS-SC-25).
From June 2015 to December 2018, RS-SCs were longitudinally measured in 765 patients with different cancer diagnoses at baseline (T0) and 3 months later (T1). The EORTC QLQ-C30, Connor-Davidson Resilience Scale, Hospital Anxiety and Depression Scale, and Allostatic Load Index were measured concurrently as anchors. Anchor-based methods (linear regression, within-group), distribution-based methods(within-group), and receiver operating characteristic curves (ROCs, within-subject) were performed to evaluate the MCIDs.
623 of 765 (84.1%) patients had paired RS-SCs scores. Moderate correlations were identified between the change in RS-SCs and change in anchors (r = 0.38-0.44, all p < 0.001). Linear regression estimated + 8.9 and - 6.7 as the MCIDs of RS-SC-25, and + 3.4 and - 2.5 for RS-SC-10. Distribution-based methods estimated + 9.9 and - 9.9 as the MCIDs of RS-SC-25, and + 4.0 and - 4.0 for RS-SC-10. ROC estimated + 5.5 and - 4.5 as the MCIDs of RS-SC-25, and + 2.0 and - 1.5 for RS-SC-10.
The most reliable MCID is around 5 points for RS-SC-25 and 2 points for RS-SC-10. RS-SCs are more responsive to the worsening status of resilience in patients with cancer and these estimates could be useful in future resilience-based intervention trials.
基金：
This research was funded by grants from National Natural Science Foundation
of China (No.71904033), Humanity and Social Science Youth Foundation
of Ministry of Education of China (No.19YJCZH227), Humanity and Social
Science Foundation of Department of Education of Guangdong Province
(No.2020WTSCX009), Humanity and Social Science Foundation of Guangzhou
University of Chinese Medicine (No.2020SKXK01), Medical Scientific
Research Foundation of Guangdong Province (No.A2019484), Research Fund
for Talented Scholars of Guangzhou University of Chinese Medicine (No.
A1-AFD018), and Innovative Project of Guangzhou University of Chinese
Medicine (No.2016KYTD08).
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2019]版：
大类|4 区医学
小类|3 区卫生保健与服务
最新[2025]版：
大类|2 区医学
小类|2 区卫生保健与服务2 区卫生政策与服务
JCR分区：
出版当年[2018]版：
Q2HEALTH POLICY & SERVICESQ2HEALTH CARE SCIENCES & SERVICES
最新[2023]版：
Q1HEALTH CARE SCIENCES & SERVICESQ1HEALTH POLICY & SERVICES
第一作者机构：[1]Guangzhou University of Chinese Medicine, Guangzhou 510006, Guangdong Province, China.
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Zeng Jie Ye,Zhang Zhang,Ying Tang,et al.Minimum clinical important difference for resilience scale specific to cancer: a prospective analysis.[J].HEALTH AND QUALITY OF LIFE OUTCOMES.2020,18(1):doi:10.1186/s12955-020-01631-6.
APA：
Zeng Jie Ye,Zhang Zhang,Ying Tang,Jian Liang,Xiao Ying Zhang...&Yuan Liang Yu.(2020).Minimum clinical important difference for resilience scale specific to cancer: a prospective analysis..HEALTH AND QUALITY OF LIFE OUTCOMES,18,(1)
MLA：
Zeng Jie Ye,et al."Minimum clinical important difference for resilience scale specific to cancer: a prospective analysis.".HEALTH AND QUALITY OF LIFE OUTCOMES 18..1(2020)
